Product Images Helidac Therapy

LIDAC® is a medication that includes bismuth subs allcylate/fnetronidazole/tetfacycline Hdl. The medication consists of two pink tablets, a capsule, and a white tablet. It should be taken with a glass of water. It appears to be manufactured by Casper Pharma LLC and is distributed in East Brunswick, NJ. The Lot number and expiration date are provided, along with instructions on how to take the medication. There are also some unclear characters and symbols present in the text.*

This is a table showing the incidence of adverse reactions reported during clinical trials of a treatment containing bismuth subsalicylate, metronidazole, and tetracycline. The table lists the percentage of patients who experienced each adverse reaction, with the most common being nausea (experienced by 120 out of 266 patients), diarrhea (68%), and abdominal pain (68%). Other reported adverse reactions are also listed.*

This is a table showing the H. pylori Eradication Rates in Patients with Active Duodenal Ulcer Disease obtained from a study known as 'Studyland 3'. The table shows the study number, eradication rate in Duodenal Ulcer patients and 95% Confidence Intervals. There are two studies in this table- Study T and Study 3, with Study T having an eradication rate of 89%, and Study 3 having an eradication rate of 70% - 92%.*

This table shows the H. Pylori eradication rates in patients with a history of duodenal ulcer disease from Study 4. It includes data on the evaluable population and the intent-to-treat population for both the HELIDAC therapy and control therapy groups. The eradication rates ranged from 1% to 7%, with corresponding confidence intervals. There is also a note stating that the lower limit for a calculation was truncated to 0 for reporting purposes.*